L-threonine High

Dosage for Threonine is highly individualized and depends heavily on the route of administration and the underlying condition being treated.

• Parenteral Nutrition (IV): In the context of Total Parenteral Nutrition (TPN), Threonine is dosed as part of a total amino acid requirement. For a stable adult, the typical protein requirement is 0.8 to 1.5 grams per kilogram of body weight per day. Threonine usually comprises approximately 4% to 5% of the total amino acid content in these solutions. For example, in a 1000 mL infusion of an 8.5% amino acid solution, there may be approximately 3.4 grams of Threonine.
• Oral Supplementation for Neurological Support: In research settings for spasticity, doses have ranged from 2 grams to 7.5 grams per day, usually divided into three or four equal doses. However, these high doses are not standard for general health and must be monitored by a specialist.
• General Nutritional Support: Standard oral doses for dietary deficiency typically range from 500 mg to 1000 mg once or twice daily.

Pediatric dosing is critical and must be calculated by a pediatric dietitian or neonatologist.

• Neonates and Infants: Amino acid requirements are much higher in infants (up to 2.5 to 3.5 g/kg/day of total protein). Threonine is essential for growth and brain development in this population.
• Children (1-12 years): Dosing is based on body weight and metabolic demand. Excessive intake in children can lead to hyperammonemia (excess ammonia in the blood).

Renal Impairment

Patients with impaired kidney function require significant dosage reductions. Because the kidneys are responsible for excreting nitrogenous waste products from amino acid metabolism, standard doses of Threonine can lead to azotemia (high levels of nitrogen-containing compounds in the blood). Healthcare providers will monitor Blood Urea Nitrogen (BUN) and Creatinine levels closely.

Hepatic Impairment

In patients with severe liver disease or hepatic encephalopathy, the metabolism of Threonine and other amino acids is impaired. This can lead to an accumulation of ammonia, which is toxic to the brain. Dosing must be carefully titrated, and specialized 'Hepatamine' solutions (rich in branched-chain amino acids but lower in others like threonine) may be used instead.

Elderly Patients

Older adults often have decreased glomerular filtration rates (GFR). Dosing should start at the lower end of the spectrum, with frequent monitoring of renal function and electrolyte balance.

• Intravenous Administration: This must be performed by a healthcare professional. Infusion rates must be controlled via an infusion pump to prevent 'solute overload' or rapid changes in blood sugar.
• Oral Forms: If taking Threonine capsules or tablets, it is generally recommended to take them with food to minimize gastrointestinal upset. However, for specific neurological uses, some protocols suggest taking it on an empty stomach to avoid competition with other dietary amino acids for absorption.
• Storage: Store oral supplements in a cool, dry place away from direct sunlight. IV solutions must be stored according to the manufacturer's instructions, often requiring protection from light and specific temperature ranges.

If you are taking Threonine on a schedule and miss a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and resume your regular schedule. Do not double the dose to catch up, as this can lead to an acute spike in plasma amino acid levels.

Signs of a Threonine overdose (or excessive amino acid intake) include:

• Nausea and vomiting
• Severe headache
• Confusion or lethargy (signs of hyperammonemia)
• Increased urination and thirst
• Rapid heart rate

In the event of a suspected overdose, especially with IV administration, the infusion should be stopped immediately, and emergency medical services should be contacted. Treatment is supportive, focusing on fluid balance and ammonia reduction.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking this medication without medical guidance, as sudden changes in amino acid intake can affect your metabolic stability.

Most patients receiving Threonine as part of a balanced nutritional program tolerate it well. However, when used in higher therapeutic doses, the following common side effects may occur:

• Gastrointestinal Distress: Nausea, bloating, and mild stomach cramps are frequently reported, particularly with oral administration. This usually subsides as the body adjusts to the supplement.
• Headache: A mild to moderate headache may occur shortly after administration, possibly due to changes in amino acid concentrations in the brain.
• Somnolence (Drowsiness): Because Threonine is a precursor to glycine, it may have a mild sedative effect in some individuals.

• Dizziness: Some patients report a feeling of lightheadedness or vertigo.
• Anorexia: A temporary loss of appetite may occur, especially when Threonine is used in high doses for neurological conditions.
• Diarrhea: Osmotic changes in the gut can lead to loose stools if high doses of oral Threonine are consumed.

• Hyperammonemia: An abnormal increase in blood ammonia levels. This is a rare but serious metabolic complication, more common in patients with underlying liver issues or infants.
• Metabolic Acidosis: An imbalance in the body's acid-base status, potentially caused by the hydrochloride salts often used in amino acid IV formulations.
• Allergic Reactions: While rare, some patients may develop a rash, itching, or hives. This is more frequent when Threonine is a component of a Plant or Food Allergenic Extract [EPC].

> Warning: Stop taking Threonine and call your doctor immediately or seek emergency care if you experience any of the following:

• Anaphylaxis: Symptoms include swelling of the face, lips, or tongue; difficulty breathing; wheezing; and a rapid, weak pulse. This is a life-threatening emergency.
• Encephalopathy: Signs include severe confusion, agitation, tremors, or loss of consciousness. This may indicate that the body is unable to process the nitrogen from the amino acid, leading to brain toxicity.
• Severe Azotemia: Marked by a significant decrease in urine output, swelling in the legs and ankles (edema), and shortness of breath, indicating kidney strain.
• Hepatic Dysfunction: Yellowing of the eyes or skin (jaundice), dark urine, and right-sided abdominal pain.

Prolonged use of Threonine, particularly in unbalanced ratios with other amino acids, can lead to:

• Amino Acid Imbalance: Excess Threonine can interfere with the transport of other essential amino acids like Phenylalanine and Tyrosine into the brain, potentially affecting mood and cognitive function.
• B-Vitamin Depletion: The metabolism of Threonine requires Vitamin B6 (pyridoxine). Long-term high-dose use may increase the body's requirement for this vitamin.
• Fatty Liver Changes: In the context of long-term TPN, imbalances in amino acids can contribute to TPN-associated liver disease.

No FDA black box warnings currently exist for Threonine as a standalone ingredient. However, parenteral amino acid solutions often carry warnings regarding the risk of Aluminum Toxicity in patients with renal impairment, particularly premature infants. Long-term parenteral administration can lead to aluminum accumulation in the bones and central nervous system.

Report any unusual symptoms or changes in your health to your healthcare provider immediately. Regular blood tests are often necessary to ensure that Threonine levels remain within a safe and therapeutic range.

Threonine is a potent metabolic agent. It should never be viewed as 'just a supplement' when used in clinical dosages. The primary safety concern involves the body's ability to process the nitrogen load that comes with amino acid administration. If the liver or kidneys are not functioning optimally, Threonine can contribute to a buildup of toxic waste products.

As of 2026, there are no specific FDA black box warnings for Threonine. However, healthcare providers must adhere to the general warnings for all intravenous amino acid products, which emphasize the risk of pulmonary vascular precipitates (solid particles forming in the lungs) if the solution is not prepared correctly with phosphate and calcium.

• Allergic Reactions / Anaphylaxis Risk: Patients with known sensitivities to specific protein sources (such as soy or dairy, if the amino acids are derived from these) must be monitored. If Threonine is being used as part of an Allergenic Extract [EPC], the risk of a controlled allergic response is intentional but must be supervised by an allergist.
• Nitrogen Balance: Threonine must be administered with adequate non-protein calories (carbohydrates and fats). Without enough energy from other sources, the body will burn Threonine for fuel, leading to a negative nitrogen balance and increased stress on the kidneys.
• Hyperammonemia: This is a critical risk in pediatric patients and those with urea cycle disorders. Ammonia is a byproduct of Threonine metabolism; if it cannot be converted to urea, it will accumulate and cause neurological damage.
• Fluid Overload: Because Threonine is often given via IV, there is a risk of fluid overload, especially in patients with congestive heart failure or pre-existing edema.

Patients receiving therapeutic Threonine require regular laboratory monitoring:

• Serum Electrolytes: Sodium, potassium, chloride, and bicarbonate levels.
• Renal Function: Serum creatinine and Blood Urea Nitrogen (BUN) should be checked at least weekly during IV therapy.
• Liver Function Tests (LFTs): To ensure the liver is processing the amino acid load without strain.
• Blood Glucose: Amino acids can influence insulin secretion and blood sugar levels.
• Plasma Amino Acid Profiling: In specialized cases, the actual level of Threonine in the blood may be measured to prevent toxicity.

Because Threonine can cause drowsiness or dizziness in some patients (due to its conversion to glycine), you should not drive or operate heavy machinery until you know how Threonine affects you. Use caution during the first few days of treatment or after any dose increase.

Alcohol should be avoided while taking therapeutic doses of Threonine. Alcohol can strain the liver and interfere with the urea cycle, significantly increasing the risk of hyperammonemia and other metabolic complications. Furthermore, alcohol may exacerbate the sedative effects of Threonine.

In the context of TPN, Threonine (as part of an amino acid mix) should be tapered slowly rather than stopped abruptly. Sudden discontinuation can lead to 'rebound' hypoglycemia (low blood sugar) because the body has adjusted its insulin production to the constant infusion of nutrients. For oral supplements, tapering is generally not required unless very high doses were used.

> Important: Discuss all your medical conditions, including any history of liver disease, kidney disease, or metabolic disorders, with your healthcare provider before starting Threonine.

While there are few absolute contraindications for an essential amino acid, Threonine should not be used in combination with:

• Sodium Phenylbutyrate: Used for urea cycle disorders. While both are used in metabolic medicine, improper mixing can interfere with the nitrogen-scavenging goals of the medication.
• Specific IV Medications: Threonine-containing IV solutions should never be co-administered through the same line as Ceftriaxone in neonates due to the risk of fatal precipitates.

• Levodopa (L-Dopa): Threonine is a Large Neutral Amino Acid (LNAA). It competes with Levodopa for the same transport carrier across the blood-brain barrier. Taking high doses of Threonine may reduce the effectiveness of Levodopa in treating Parkinson’s disease symptoms.
• Antipsychotic Medications: Since Threonine increases glycine levels, it may theoretically modulate the effects of NMDA-receptor-related drugs. This interaction is complex and requires close psychiatric monitoring.

• Diuretics (e.g., Furosemide, Hydrochlorothiazide): Diuretics can alter the excretion of electrolytes and nitrogenous waste. When taken with Threonine, they may increase the risk of dehydration and azotemia.
• Corticosteroids: These drugs promote protein breakdown (catabolism). This can counteract the protein-sparing effects of Threonine and lead to higher levels of circulating ammonia and urea.

• High-Protein Meals: Consuming a very high-protein diet while taking Threonine supplements can overwhelm the body's nitrogen-processing capacity, leading to nausea and fatigue.
• Dairy Products: Calcium in dairy may interact with the Calcium Chelating Activity [MoA] of Threonine, potentially reducing the absorption of both the amino acid and the mineral.

• Vitamin B6 (Pyridoxine): B6 is a required cofactor for the enzyme threonine dehydratase. Taking Threonine without adequate B6 may lead to inefficient metabolism, while excessive B6 supplementation may accelerate Threonine breakdown.
• Other Amino Acids: Taking high doses of Threonine can interfere with the absorption of Valine, Leucine, and Isoleucine due to competition for the same intestinal transporters.

• Urine Ketone Tests: Threonine metabolism produces alpha-ketobutyrate, which may cause false-positive results on certain urine ketone dipstick tests.
• Serum Creatinine: High amino acid intake can transiently elevate creatinine levels, potentially leading to a misinterpretation of kidney function.

For each interaction, the primary mechanism is usually competitive inhibition at the transporter level or metabolic demand on the liver and kidneys. The clinical consequence is typically reduced efficacy of the co-administered drug or an increased risk of metabolic toxicity. Management usually involves spacing doses several hours apart or adjusting the total protein intake.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including 'natural' protein powders or BCAAs.

Threonine must NEVER be used in the following circumstances:

1. 1Hypersensitivity: Any known severe allergy to L-threonine or any component of the IV formulation (such as specific sulfites used as preservatives).
2. 2Inborn Errors of Amino Acid Metabolism: Conditions such as Urea Cycle Disorders (e.g., Ornithine Transcarbamylase deficiency) where the body cannot process nitrogen. Administering Threonine in these cases can lead to rapid, fatal ammonia toxicity.
3. 3Severe Hepatic Coma: In the acute phase of hepatic encephalopathy, the liver cannot process any amino acids, and administration will worsen brain swelling.
4. 4Severe Renal Failure (without Dialysis): When the GFR is extremely low and the patient is not on dialysis, the kidneys cannot clear the urea produced from Threonine metabolism.

Conditions requiring careful risk-benefit analysis include:

• Congestive Heart Failure (CHF): Due to the risk of fluid overload during IV administration.
• Acidosis: Since some Threonine formulations have acidifying activity, they may worsen pre-existing metabolic or respiratory acidosis.
• Diabetes Mellitus: Amino acids can stimulate glucagon and insulin release, potentially complicating blood sugar management.

Patients who are allergic to certain protein sources used in the manufacture of amino acids (such as soy-derived proteins) may show cross-reactivity. Furthermore, if a patient has had a reaction to other neutral amino acids (like Serine), they should be monitored closely when starting Threonine.

> Important: Your healthcare provider will evaluate your complete medical history, including genetic metabolic screenings, before prescribing Threonine.

FDA Pregnancy Category: C (as part of parenteral nutrition).

Threonine is a natural and essential component of the human diet. During pregnancy, the demand for amino acids increases to support fetal growth. However, there are no adequate and well-controlled studies on the use of high-dose therapeutic Threonine in pregnant women.

• Trimester-specific risks: In the first trimester, metabolic stability is crucial; excessive amino acid intake should be avoided. In the third trimester, the risk of fluid retention and preeclampsia must be considered if IV Threonine is used.
• Teratogenicity: There is no evidence that Threonine is teratogenic (causes birth defects) when used within nutritional requirements.

Threonine is a natural constituent of human breast milk. Supplemental Threonine is generally considered safe for nursing mothers when used in nutritional doses. However, the effects of high-dose therapeutic Threonine on the nursing infant are unknown. Healthcare providers typically recommend monitoring the infant for signs of GI distress or changes in feeding patterns if the mother is on high-dose therapy.

Threonine is vital for pediatric patients, particularly for the development of the skeletal system and the CNS.

• Approved age ranges: Approved for use in infants (including pre-term) as part of TPN.
• Special Dosing: Pediatric doses are strictly weight-based.
• Warnings: Premature infants are at high risk for hyperammonemia and aluminum toxicity from IV solutions. Growth rates should be monitored regularly in children on long-term Threonine therapy.

Elderly patients are more likely to have age-related declines in renal and hepatic function.

• Fall Risk: Because Threonine can cause somnolence (sleepiness), it may increase the risk of falls in the elderly.
• Renal Clearance: Dose reductions are often necessary to prevent azotemia.
• Polypharmacy: Older adults are often on multiple medications (like diuretics or ACE inhibitors) that can interact with Threonine's effect on the kidneys.

In patients with a GFR < 30 mL/min, Threonine must be used with extreme caution. Nitrogen intake must be strictly limited to prevent the accumulation of urea. For patients on hemodialysis, Threonine is often removed by the dialysis process, and 'post-dialysis' supplementation may be required to prevent deficiency.

For patients with Child-Pugh Class C liver disease, Threonine is generally contraindicated or used only in specialized 'liver-safe' amino acid blends. The risk of triggering hepatic encephalopathy is the primary concern.

> Important: Special populations require individualized medical assessment and frequent laboratory monitoring to ensure safety.

Threonine (2-amino-3-hydroxybutyric acid) is a polar, uncharged amino acid. Its primary molecular mechanism involves its role as a substrate for protein synthesis. However, its specific pharmacological actions include:

1. 1Mucin Synthesis: Threonine is highly utilized by the goblet cells in the gut to create the protein backbone of mucin. This is essential for the intestinal mucosal barrier.
2. 2Glycine Precursor: Through the action of the enzyme threonine aldolase, it is cleaved into glycine and acetaldehyde. Glycine acts on strychnine-sensitive receptors in the spinal cord to provide inhibitory tone, which is the basis for its use in spasticity.
3. 3Chelation: The hydroxyl group on the side chain allows Threonine to participate in Calcium Chelating Activity [MoA], binding divalent cations.

• Dose-Response: There is a linear relationship between Threonine intake and plasma concentration up to a saturation point of the transporters.
• Onset: When given IV, the metabolic effects are immediate. Orally, peak plasma concentrations (Tmax) are reached within 1-2 hours.
• Duration: The effects on nitrogen balance last as long as the infusion continues. The neurological effects of oral doses typically last 4-6 hours.

| Parameter | Value |

|---|---|

| Bioavailability | ~90% (Oral); 100% (IV) |

| Protein Binding | Minimal (<5%) |

| Half-life | 2.5 - 4 hours |

| Tmax | 1 - 2 hours |

| Metabolism | Hepatic (Dehydratase/Aldolase) |

| Excretion | Renal (<5% as unchanged drug) |

• Molecular Formula: C4H9NO3
• Molecular Weight: 119.12 g/mol
• Solubility: Highly soluble in water (97 g/L at 25°C).
• Structure: Contains an alpha-amino group, an alpha-carboxylic acid group, and a side chain containing a hydroxyl group, making it a polar amino acid.

Threonine is classified as an Essential Amino Acid. It is related to other hydroxy-amino acids like Serine. In the therapeutic hierarchy, it is grouped with other parenteral nutrients and metabolic modifiers.